COVID-19: angiotensin-converting enzyme 2 (ACE2) expression and tissue susceptibility to SARS-CoV-2 infection

S Beyerstedt, EB Casaro, ÉB Rangel - European journal of clinical …, 2021 - Springer
COVID-19 pandemic is caused by the novel coronavirus SARS-CoV-2. Angiotensin-
converting enzyme 2 (ACE2) is not only an enzyme but also a functional receptor on cell …

COVID-19 and cardiovascular disease: from basic mechanisms to clinical perspectives

M Nishiga, DW Wang, Y Han, DB Lewis… - Nature Reviews …, 2020 - nature.com
Abstract Coronavirus disease 2019 (COVID-19), caused by a strain of coronavirus known as
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has become a global …

Renin–angiotensin–aldosterone system inhibitors and risk of Covid-19

HR Reynolds, S Adhikari, C Pulgarin… - … England Journal of …, 2020 - Mass Medical Soc
Background There is concern about the potential of an increased risk related to medications
that act on the renin–angiotensin–aldosterone system in patients exposed to coronavirus …

Renin–angiotensin–aldosterone system inhibitors in patients with Covid-19

M Vaduganathan, O Vardeny, T Michel… - … England Journal of …, 2020 - Mass Medical Soc
RAAS Inhibitors in Patients with Covid-19 The effects of renin–angiotensin–aldosterone
system blockers on angiotensin-converting enzyme 2 levels and activity in humans are …

COVID-19, renin-angiotensin system and endothelial dysfunction

R Amraei, N Rahimi - Cells, 2020 - mdpi.com
The newly emergent novel coronavirus disease 2019 (COVID-19) outbreak, which is caused
by SARS-CoV-2 virus, has posed a serious threat to global public health and caused …

Continuation versus discontinuation of renin–angiotensin system inhibitors in patients admitted to hospital with COVID-19: a prospective, randomised, open-label trial

JB Cohen, TC Hanff, P William, N Sweitzer… - The lancet respiratory …, 2021 - thelancet.com
Background Biological considerations suggest that renin–angiotensin system inhibitors
might influence the severity of COVID-19. We aimed to evaluate whether continuing versus …

[HTML][HTML] Angiotensin-converting enzyme 2—at the heart of the COVID-19 pandemic

GY Oudit, K Wang, A Viveiros, MJ Kellner… - Cell, 2023 - cell.com
ACE2 is the indispensable entry receptor for SARS-CoV and SARS-CoV-2. Because of the
COVID-19 pandemic, it has become one of the most therapeutically targeted human …

Controversies of renin–angiotensin system inhibition during the COVID-19 pandemic

AM South, L Tomlinson, D Edmonston… - Nature Reviews …, 2020 - nature.com
The current COVID-19 pandemic is associated with unprecedented morbidity and mortality.
Early reports suggested an association between disease severity and hypertension but did …

Roles of human serum albumin in prediction, diagnoses and treatment of COVID-19

G Rabbani, SN Ahn - International Journal of Biological Macromolecules, 2021 - Elsevier
The severe acute respiratory syndrome corona virus-2 (SARS-CoV-2) keeps on destroying
normal social integrity worldwide, bringing about extraordinary medical services, cultural …

Plasma ACE2 and risk of death or cardiometabolic diseases: a case-cohort analysis

S Narula, S Yusuf, M Chong, C Ramasundarahettige… - The Lancet, 2020 - thelancet.com
Background Angiotensin-converting enzyme 2 (ACE2) is an endogenous counter-regulator
of the renin–angiotensin hormonal cascade. We assessed whether plasma ACE2 …